Previously located in Michigan with strong ties to University of Michigan Ann Arbor, Nymirum, Inc. is a drug discovery company developing a proprietary platform designed rapidly to solve high-resolution RNA 3D structures and therapeutically target RNA using small molecules. The firm is offering a platform that provides new molecules and scaffolds for newly validated RNA targets, which are fed into the traditional med chem and biology pipeline. Utilizing small molecules avoids the drug delivery difficulties inherent in nucleic acid-based approaches and enables orally available treatments for a broad range of diseases. The company enables the industry to attack a new generation of higher-probability targets while leveraging their existing small molecule library.
